Jennifer Cook Biography and Net Worth

Director of Jazz Pharmaceuticals

Jennifer E. Cook brings over 30 years of biopharmaceutical experience with significant C-suite, global product development and commercialization expertise, with a focus on transformative growth. After receiving her MBA from the University of California, Berkeley, Ms. Cook joined the team launching Herceptin, the first monoclonal antibody that blocks a cancer-causing protein. In 2016, Ms. Cook was recognized as Woman of the Year by the Healthcare Businesswoman's Association.

Ms. Cook was the Chief Executive Officer at GRAIL, Inc., a privately-held early cancer detection diagnostic company from January 2018 to June 2019. Prior to that, Ms. Cook worked at Roche Pharmaceuticals/Genentech for 25 years where she held a number of senior management positions covering the full lifecycle of product development and commercialization. From 2010 to 2013, she oversaw Genentech's U.S. Immunology and Ophthalmology Business Unit, and from 2013 to 2016, she led Roche's European commercial business. She also served as Roche's Global Head of Clinical Operations throughout 2017. Ms. Cook currently serves as non-executive director on the boards of two publicly-held biotechnology companies, Denali Therapeutics Inc., and BridgeBio Pharma, Inc. Ms. Cook received a B.A. in human biology and a M.S. in biology from Stanford University and an M.B.A. from the Haas School of Business at University of California, Berkeley.

What is Jennifer E. Cook's net worth?: The estimated net worth of Jennifer E. Cook is at least $598,855.66 as of December 2nd, 2022. Ms. Cook owns 5,471 shares of Jazz Pharmaceuticals stock worth more than $598,856 as of April 27th. This net worth evaluation does not reflect any other investments that Ms. Cook may own. Learn More about Jennifer E. Cook's net worth.
How do I contact Jennifer E. Cook?: The corporate mailing address for Ms. Cook and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Jennifer E. Cook's contact information.
Has Jennifer E. Cook been buying or selling shares of Jazz Pharmaceuticals?: Jennifer E. Cook has not been actively trading shares of Jazz Pharmaceuticals during the last quarter. Most recently, Jennifer E. Cook sold 420 shares of the business's stock in a transaction on Friday, December 2nd. The shares were sold at an average price of $154.68, for a transaction totalling $64,965.60. Following the completion of the sale, the director now directly owns 5,471 shares of the company's stock, valued at $846,254.28. Learn More on Jennifer E. Cook's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Robert Iannone (EVP), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 10 times. They sold a total of 13,870 shares worth more than $1,827,470.63. The most recent insider tranaction occured on March, 6th when CAO Patricia Carr sold 1,936 shares worth more than $231,623.04. Insiders at Jazz Pharmaceuticals own 4.4% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 3/6/2024.

Jennifer E. Cook Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/2/2022	Sell	420	$154.68	$64,965.60	5,471

Jennifer E. Cook Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $109.46

$106.73

$110.82

50 Day Range

MA: $118.25

$107.10

$132.77

2 Week Range

Now: $109.46

$106.61

$146.70

Volume

480,575 shs

Average Volume

504,507 shs

Market Capitalization

$6.90 billion

P/E Ratio

17.89

Dividend Yield

N/A

Beta

0.59

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>